The Complainant manufactures, develops and sells biotech products in Canada, the USA and Europe and also owns the novozymes.com domain name. The Complainant registered its mark NOVOZYMES in Canada as early as March, 2004. The disputed Domain Name was registered on January 3, 2014 and the Respondent did not file a response to the Complaint.
The Panel held that the Domain Name redirects users to websites of companies competing with the Complainant by selling enzymes. Furthermore, the Complainant showed that the domain name novozymes.ca was offered for sale on a popular domain brokerage site, which was sufficient to demonstrate bad faith under the Policy.
You can read the decision here.